Published in

American Society for Microbiology, Clinical Microbiology Reviews, 3(35), 2022

DOI: 10.1128/cmr.00014-22

Links

Tools

Export citation

Search in Google Scholar

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant

Journal article published in 2022 by Hao Zhou ORCID, Michelle Møhlenberg ORCID, Jigarji C. Thakor, Hardeep Singh Tuli, Pengfei Wang, Yehuda G. Assaraf, Kuldeep Dhama, Shibo Jiang
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps evolving and mutating into newer variants over time, which gain higher transmissibility, disease severity, and spread in communities at a faster rate, resulting in multiple waves of surge in Coronavirus Disease 2019 (COVID-19) cases. A highly mutated and transmissible SARS-CoV-2 Omicron variant has recently emerged, driving the extremely high peak of infections in almost all continents at an unprecedented speed and scale.